Shannon Westin
Shannon Westin
Unknown affiliation
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
F Janku, JJ Wheler, SN Westin, SL Moulder, A Naing, AM Tsimberidou, ...
Journal of clinical oncology 30 (8), 777, 2012
4452012
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer
H Liang, LWT Cheung, J Li, Z Ju, S Yu, K Stemke-Hale, T Dogruluk, Y Lu, ...
Genome research 22 (11), 2120-2129, 2012
2412012
Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome
SN Westin, RA Lacour, DL Urbauer, R Luthra, DC Bodurka, KH Lu, ...
Journal of Clinical Oncology 26 (36), 5965, 2008
1882008
AKT inhibition in solid tumors with AKT1 mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251, 2017
1652017
Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology
PT Soliman, M Frumovitz, CC Sun, R Dos Reis, KM Schmeler, AM Nick, ...
Gynecologic oncology 123 (2), 333-336, 2011
1182011
Clinical cancer advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology
J Heymach, L Krilov, A Alberg, N Baxter, SM Chang, RB Corcoran, ...
Journal of Clinical Oncology 36 (10), 1020-1044, 2018
1152018
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade …
UA Matulonis, GM Wulf, WT Barry, M Birrer, SN Westin, S Farooq, ...
Annals of Oncology 28 (3), 512-518, 2017
1132017
A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer
PT Soliman, SN Westin, S Dioun, CC Sun, E Euscher, MF Munsell, ...
Gynecologic oncology 146 (2), 234-239, 2017
1122017
Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology–RTOG 1203
AH Klopp, AR Yeung, S Deshmukh, KM Gil, L Wenzel, SN Westin, ...
Journal of Clinical Oncology 36 (24), 2538, 2018
992018
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
C Sun, Y Fang, J Yin, J Chen, Z Ju, D Zhang, X Chen, CP Vellano, ...
Science translational medicine 9 (392), 2017
912017
Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer
GM Rauch, H Kaur, H Choi, RD Ernst, AH Klopp, P Boonsirikamchai, ...
Radiographics 34 (4), 1082-1098, 2014
822014
Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device
N Pal, RR Broaddus, DL Urbauer, N Balakrishnan, A Milbourne, ...
Obstetrics and gynecology 131 (1), 109, 2018
782018
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH …
I Brana, R Berger, T Golan, P Haluska, J Edenfield, J Fiorica, ...
British journal of cancer 111 (10), 1932-1944, 2014
702014
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ...
The Lancet Oncology 20 (4), 570-580, 2019
692019
Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence
A Carroll, PT Ramirez, SN Westin, PT Soliman, MF Munsell, AM Nick, ...
Gynecologic oncology 135 (3), 455-461, 2014
682014
Overall survival after pelvic exenteration for gynecologic malignancy
SN Westin, V Rallapalli, B Fellman, DL Urbauer, N Pal, MM Frumovitz, ...
Gynecologic oncology 134 (3), 546-551, 2014
682014
What women with ovarian cancer think and know about genetic testing
RA Lacour, MS Daniels, SN Westin, LA Meyer, CC Burke, KA Burns, ...
Gynecologic oncology 111 (1), 132-136, 2008
622008
A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers
U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ...
Clinical Cancer Research 24 (9), 2050-2059, 2018
602018
Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer
ND Fleming, M Frumovitz, KM Schmeler, R Dos Reis, MF Munsell, PJ Eifel, ...
Gynecologic oncology 136 (1), 48-53, 2015
582015
A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma
J Pakish, PT Soliman, M Frumovitz, SN Westin, KM Schmeler, R Dos Reis, ...
Gynecologic oncology 132 (2), 366-371, 2014
552014
The system can't perform the operation now. Try again later.
Articles 1–20